HER2-NEGATIVE BREAST CANCER

This study tests whether giving hormone therapy for 6 months before surgery can help remove all cancer in one piece, reducing the need for a full mastectomy. It includes 8 postmenopausal women with early-stage, low-risk, ER-positive breast cancer. The main goal is to see if the t…

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating. The goa…

This study tests a drug called alpelisib combined with standard hormone therapy for people with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) whose cancer has worsened on hormone therapy alone. About 44 participants will take alpelisib daily along…

This study tests whether adding a heat treatment called modulated electro-hyperthermia to standard chemotherapy can shrink tumors more than chemo alone in women with HER2-negative breast cancer. About 71 participants with stage II-III disease will receive either chemo plus heat o…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a certain type of advanced breast cancer (HR+/HER2-) live longer without the disease getting worse. About 110 participants will receive either the drug alone or the combination. Th…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors (like breast, ovarian, lung, and pancreatic cancers) that have no curative options. The main goal is to find safe doses and under…

This study tests a new drug called azenosertib combined with two standard chemotherapy drugs (carboplatin and pembrolizumab) in people with metastatic triple-negative breast cancer. The goal is to find the safest dose and see if the combination shrinks tumors. About 78 adults wit…

This phase 3 study tests whether giving a combination of two hormone-blocking drugs (fulvestrant and anastrozole) or fulvestrant alone before surgery works better than the standard anastrozole alone for shrinking estrogen receptor-positive breast cancer in postmenopausal women. A…

This study tests a new drug called NUV-1511 in people with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors in specific cancers like breast, prostate, pancreatic…

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it is …

This phase 3 trial tests whether the drug sacituzumab govitecan can prevent breast cancer from coming back in patients with HER2-negative breast cancer who still have cancer cells after initial chemotherapy. About 1,332 participants will receive either the new drug or standard tr…

This study looks at whether a blood test that tracks tumor DNA can help doctors switch treatments earlier in people with stage IV breast cancer. The goal is to see if acting on this early signal can keep the cancer under control longer than waiting for scans to show growth. About…